{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:05:03Z","timestamp":1784178303774,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Genetic and molecular alterations in cancer cells can serve as therapeutic targets and enable more precise, individualized treatment strategies. In rare tumors with limited systemic treatment options, molecular profiling may help identify therapeutic opportunities when conventional approaches are exhausted. We report the case of a 72-year-old woman with a long-standing, multiply recurrent clival chordoma and no remaining surgical or radiation options who experienced a meaningful clinical and metabolic response to targeted therapy. Comprehensive tumor molecular profiling identified an activating isocitrate dehydrogenase 1 (IDH1) p. R132C mutation, which guided off-label treatment with the IDH1 inhibitor ivosidenib. Treatment was well tolerated and associated with durable radiographic response with tumor reduction, partial metabolic response on FDG-PET imaging, and clinically significant improvement in neurological symptoms and quality of life. This case highlights the value of molecular tumor board\u2013guided interpretation of genomic alterations and illustrates the potential role of IDH-targeted therapy in select patients with recurrent chordoma.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag240","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:58:53Z","timestamp":1782302333000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapy in recurrent clival chordoma: a case report of response to ivosidenib"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-5441","authenticated-orcid":false,"given":"Elnaz","family":"Rahbarlayegh","sequence":"first","affiliation":[{"name":"The Lundquist Institute , Torrance, CA 90502,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[{"name":"The Lundquist Institute , Torrance, CA 90502,","place":["United States"]},{"name":"Asthra Health, Santa Monica, CA90404,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026071600261940700_oyag240-B1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"key":"2026071600261940700_oyag240-B2","first-page":"326","article-title":"The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation","volume":"1846","author":"Molenaar","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"2026071600261940700_oyag240-B3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"2026071600261940700_oyag240-B4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026071600261940700_oyag240-B5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/ng.1004","article-title":"Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome","volume":"43","author":"Pansuriya","year":"2011","journal-title":"Nat Genet"},{"key":"2026071600261940700_oyag240-B6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br J Cancer"},{"key":"2026071600261940700_oyag240-B7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"key":"2026071600261940700_oyag240-B8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature10898","article-title":"Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation","volume":"483","author":"Koivunen","year":"2012","journal-title":"Nature"},{"key":"2026071600261940700_oyag240-B9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"2026071600261940700_oyag240-B10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer","volume":"27","author":"Losman","year":"2013","journal-title":"Genes Dev"},{"key":"2026071600261940700_oyag240-B11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"2026071600261940700_oyag240-B12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2013-10-533604","article-title":"IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition","volume":"125","author":"Kernytsky","year":"2015","journal-title":"Blood"},{"key":"2026071600261940700_oyag240-B13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026071600261940700_oyag240-B14","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026071600261940700_oyag240-B15","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2026071600261940700_oyag240-B16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00701-008-1600-3","article-title":"Cranial base chordoma\u2014long term outcome and review of the literature","volume":"150","author":"Yoneoka","year":"2008","journal-title":"Acta Neurochir (Wien)"},{"key":"2026071600261940700_oyag240-B17","doi-asserted-by":"publisher","first-page":"e71-83","DOI":"10.1016\/S1470-2045(14)71190-8","article-title":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","volume":"16","author":"Stacchiotti","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026071600261940700_oyag240-B18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.2011.35.3656","article-title":"Phase II study of imatinib in advanced chordoma","volume":"30","author":"Stacchiotti","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026071600261940700_oyag240-B19","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.annonc.2025.07.011","article-title":"Corrigendum to \"sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF\/GETO)\": [Ann Oncol 26 (2015) 2168-2173]","volume":"36","author":"Bompas","year":"2025","journal-title":"Ann Oncol"},{"key":"2026071600261940700_oyag240-B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13569-016-0059-x","article-title":"Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series","volume":"6","author":"Lipplaa","year":"2016","journal-title":"Clin Sarcoma Res"},{"key":"2026071600261940700_oyag240-B21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/path.4729","article-title":"EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen","volume":"239","author":"Scheipl","year":"2016","journal-title":"J Pathol"},{"key":"2026071600261940700_oyag240-B22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10517-020-05005-2","article-title":"Key immune checkpoint PD-1\/PD-L1 signaling pathway components in the blood serum from patients with bone tumors","volume":"170","author":"Kushlinskii","year":"2020","journal-title":"Bull Exp Biol Med"},{"key":"2026071600261940700_oyag240-B23","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41467-017-01026-0","article-title":"The driver landscape of sporadic chordoma","volume":"8","author":"Tarpey","year":"2017","journal-title":"Nat Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag240\/68613003\/oyag240.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag240\/68613003\/oyag240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag240\/68613003\/oyag240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:26:22Z","timestamp":1784175982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag240\/8716327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag240","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,25]]},"article-number":"oyag240"}}